SCHEMBL17377309

SCHEMBL17377309

Nc1c(S(=O)(=O)c2ccccc2)c2ccnnc2n1C1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 4/20 0.53
GAA P10253 3/20 0.53
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
DNMT1 P26358 1/20 0.45
BLM P54132 1/20 0.45
PLEC Q15149 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
FFAR2 O15552 10/20 0.43
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
MAPK1 P28482 1/20 0.36
HTR6 P50406 2/20 0.36
CDK4 P11802 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17379340 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17377216 0.82 ALDH1A1 (0.51) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17378961 0.80 ALDH1A1 (0.47) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17378947 0.79 KDM4E (0.61) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17378960 0.79 ALDH1A1 (0.52) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17377311 0.78 ALDH1A1 (0.48) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL19743052 0.77 ALDH1A1 (0.50) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17379006 0.76 KMT2A (0.43) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17378971 0.75 KDM4E (0.43) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL19742984 0.75 KDM4E (0.62) ALDH1A1KDM4EGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US claimed
EP-3160955-A1 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP claimed
WO-2015198046-A1 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-30 WO claimed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US disclosed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US disclosed
WO-2015198046-A1 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE GPR119, IDO1, IDO2 ALDH1A1 1063/4885KDM4E 556/4885GAA 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.